[Prediction of XXXX with bedtime @entity413 level during continuous subcutaneous @entity2690 infusion in type 2 @entity6 ].

@entity1 @entity6 @entity7584 @entity2690 @entity4053 @entity7965 @entity413
OBJECTIVE: To find out the features of glycemic excursion via continuous @entity413 monitoring system (CGMS) during continuous subcutaneous @entity2690 infusion (CSII) treatment in type 2 @entity6 and discuss the possibility of predicting @entity7965 with bedtime @entity413 level. METHODS: A total of 257 @entity6 @entity1 (156 males and 101 females, aged from 27 - 88 years old) with 0.1 - 40 years diabetic history were recruited. Their HbA1c level was (10.97    2.11)%. Glycated albumin level was (31.88    7.51)%. All @entity1 were switched to CSII therapy while a 72-hour period of CGMS was performed. @entity1 were divided into @entity4053 group and non- @entity4053 group according to the reading of hypoglycemic events from CGMS data. RESULTS: (1) From CGMS profiles, the investigators found that @entity7584 was (9.66    2.00) mmol/L and SDBG (2.98    1.03) mmol/L. (2) A total of 243 @entity4053 events occurred in 118 @entity1 at early stage of CSII treatment. (3) When bedtime blood @entity413 was below 5.9 mmol/L, the youden index was maximal on a receiver operating characteristic curve. The sensitive was 54.8% and specificity 77.8%. Positive predictive value was 44.3% and negative predictive value 84.2%. So the cut-off point of bedtime blood @entity413 to predict @entity4053 might be 5.9 mmol/L. CONCLUSION: (1) @entity4053 as detected by CGMS occurs in almost 1/2 type 2 @entity6 during CSII therapy. (2) There is a higher risk of @entity4053 if the bedtime blood @entity413 concentration falls below 5.9 mmol/L.
